Latest & greatest articles for tiotropium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tiotropium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tiotropium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tiotropium

1. Tiotropium (Spiriva Respimat) - as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year

Tiotropium (Spiriva Respimat) - as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year Published 14 January 2019 www.scottishmedicines.org.uk Product update SMC2118 tiotropium 2.5 microgram solution for inhalation (Spiriva® Respimat®) Boehringer Ingelheim Limited 7 December 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product (...) and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission tiotropium (Spiriva® Respimat®) is accepted for use within NHSScotland. Indication under review: as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year. Tiotropium has previously been accepted for use

2019 Scottish Medicines Consortium

2. Effect and safety of tiotropium in early-stage chronic obstructive pulmonary disease: systematic review and meta-analysis

Effect and safety of tiotropium in early-stage chronic obstructive pulmonary disease: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

3. Tiotropium (Spiriva Respimat) add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma

Tiotropium (Spiriva Respimat) add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma Tiotropium (Spiriva ® Respimat ® ). Reference number 1882. Page 1 of 3 AWMSG Secretariat Assessment Report – Limited submission Tiotropium (Spiriva ® Respimat ® ) 2.5 microgram, inhalation solution Company: Boehringer Ingelheim Ltd Licensed indication under consideration: add-on maintenance bronchodilator treatment in patients aged 6 years to < 18 years with severe (...) asthma who experienced one or more severe asthma exacerbations in the preceding year Date of licence extension: 12 April 2018 Comparator(s) The company stated that there is no comparator and that tiotropium (Spiriva ® Respimat ® ) is an add-on treatment. Limited submission details ? The limited submission criteria were met based on a minor licence extension. Clinical effectiveness ? Tiotropium (Spiriva ® Respimat ® ) was recommended by the All Wales Medicines Strategy Group in 2017 as an add

2018 All Wales Medicines Strategy Group

4. Tiotropium

Tiotropium Top results for tiotropium - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for tiotropium The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

5. Braltus (tiotropium): risk of inhalation of capsule if placed in the mouthpiece of the inhaler

Braltus (tiotropium): risk of inhalation of capsule if placed in the mouthpiece of the inhaler Braltus (tiotropium): risk of inhalation of capsule if placed in the mouthpiece of the inhaler - GOV.UK GOV.UK uses cookies to make the site simpler. Search Braltus (tiotropium): risk of inhalation of capsule if placed in the mouthpiece of the inhaler Train patients to place the Braltus capsule in the correct chamber of the Zonda inhaler. We have received reports of patients who have inhaled a Braltus (...) in the inhaler) and to always check the mouthpiece is clear before inhaling pharmacists dispensing Braltus capsules should remind patients to always read the in the package leaflet and that they must never place a capsule directly into the mouthpiece please continue to report adverse incidents during use of the inhaler as well as suspected adverse reactions to the medicine on a Background Braltus tiotropium 10 µg per delivered dose inhalation powder is a once-a-day maintenance bronchodilator treatment

2018 MHRA Drug Safety Update

6. Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease. (PubMed)

Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease. Patients with mild or moderate chronic obstructive pulmonary disease (COPD) rarely receive medications, because they have few symptoms. We hypothesized that long-term use of tiotropium would improve lung function and ameliorate the decline in lung function in patients with mild or moderate COPD.In a multicenter, randomized, double-blind, placebo-controlled trial that was conducted in China, we randomly assigned 841 patients (...) with COPD of Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 1 (mild) or 2 (moderate) severity to receive a once-daily inhaled dose (18 μg) of tiotropium (419 patients) or matching placebo (422) for 2 years. The primary end point was the between-group difference in the change from baseline to 24 months in the forced expiratory volume in 1 second (FEV1) before bronchodilator use. Secondary end points included the between-group difference in the change from baseline to 24 months

2017 NEJM

7. Spiolto Respimat (tiotropium/olodaterol) - chronic obstructive pulmonary disease (COPD)

Spiolto Respimat (tiotropium/olodaterol) - chronic obstructive pulmonary disease (COPD) Spiolto Respimat® (tiotropium/olodaterol) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Spiolto Respimat® (tiotropium/olodaterol) Conclusion Spiolto Respimat® (tiotropium/olodaterol) combines a long-acting muscarinic antagonist (LAMA) with a long-acting beta agonist (LABA) and is approved for maintenance bronchodilator treatment to relieve symptoms in adult (...) patients with chronic obstructive pulmonary disease (COPD). The LAMA component, tiotropium (Spiriva®), and the LABA component, olodaterol (Striverdi®), each have the same indication as Spiolto Respimat®. Despite statistically significant differences in several patient-specific measures of effectiveness (e.g. quality of life) favouring Spiolto Respimat® over the individual components, the efficacy is assessed to have limited clinical relevance in patients not yet started on relevant symptom-alleviating

2017 Danish Pharmacotherapy Reviews

8. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD (Full text)

Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD Two replicate, double-blind, 6-week, incomplete-crossover studies (MORACTO 1 and 2) assessed the effects of tiotropium/olodaterol on inspiratory capacity and exercise endurance time in patients with moderate to severe chronic obstructive pulmonary disease.For each patient, four of five treatments were administered once daily for 6 weeks, with a 21-day washout between treatments: tiotropium (...) /olodaterol 2.5/5 µg or 5/5 µg, tiotropium 5 µg, olodaterol 5 µg or placebo, all via the Respimat inhaler. Primary outcomes were inspiratory capacity prior to exercise and exercise endurance time during constant work-rate cycle ergometry to symptom limitation at 75% of peak incremental work rate after 6 weeks (2 h post-dose).295 and 291 patients were treated in MORACTO 1 and 2, respectively. Tiotropium/olodaterol 2.5/5 and 5/5 µg provided significant improvements in inspiratory capacity versus placebo

2017 EvidenceUpdates PubMed

9. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma (Full text)

A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma We present results from the first phase III trial of once-daily tiotropium add-on to inhaled corticosteroids (ICS) plus one or more controller therapies in adolescents with severe symptomatic asthma.In this double-blind, parallel-group trial (NCT01277523), 392 patients aged 12-17 years were randomised to receive once-daily tiotropium 5 µg or 2.5 µg, or placebo, as an add-on to ICS plus other controller (...) therapies over 12 weeks. The primary and key secondary end-points were change from baseline (response) in peak forced expiratory volume in 1 s (FEV1) within 3 h post-dosing (FEV1(0-3h)) and trough FEV1, respectively, after 12 weeks of treatment.Tiotropium 5 µg provided numerical improvements in peak FEV1(0-3h) response, compared with placebo (90 mL; p=0.104), and significant improvements were observed with tiotropium 2.5 µg (111 mL; p=0.046). Numerical improvements in trough FEV1 response and asthma

2017 EvidenceUpdates PubMed

10. Tiotropium/olodaterol - Addendum

Tiotropium/olodaterol - Addendum 1 Translation of addendum A15-57 Tiotropium/Olodaterol – Addendum zum Auftrag A15-31 (Version 1.0; Status: 14 January 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 14 January 2016 1.0 Commission: A15-57 Version: Status: IQWiG Reports – Commission No. A15-57 Tiotropium/olodaterol – Addendum to Commission A15-31 1 (...) Addendum A15-57 Version 1.0 Tiotropium/olodaterol – Addendum to Commission A15-31 14 January 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Tiotropium/olodaterol – Addendum to Commission A15-31 Commissioning agency: Federal Joint Committee Commission awarded on: 22 December 2015 Internal Commission No.: A15-57 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im

2016 Institute for Quality and Efficiency in Healthcare (IQWiG)

11. Combination inhaled steroid and long-acting beta₂-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. (Full text)

Combination inhaled steroid and long-acting beta₂-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. The long-acting bronchodilator tiotropium and single-inhaler combination therapy of inhaled corticosteroids and long-acting beta2-agonists (ICS/LABA) are commonly used for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Combining these treatments, which have different mechanisms of action, may (...) be more effective than administering the individual components.To assess relative effects of the following treatments on markers of exacerbations, symptoms, quality of life and lung function in patients with COPD.• Tiotropium plus LABA/ICS versus tiotropium.• Tiotropium plus LABA/ICS versus LABA/ICS.We searched the Cochrane Airways Group Specialised Register of Trials (April 2015), ClinicalTrials.gov (www.ClinicalTrials.gov), the World Health Organization (WHO) trials portal and reference lists

2016 Cochrane PubMed

12. [Tiotropium/olodaterol - addendum to commission A15-31]

[Tiotropium/olodaterol - addendum to commission A15-31] Tiotropium/olodaterol: addendum zum auftrag A15-31; auftrag A15-57 [Tiotropium/olodaterol - addendum to commission A15-31] Tiotropium/olodaterol: addendum zum auftrag A15-31; auftrag A15-57 [Tiotropium/olodaterol - addendum to commission A15-31] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Tiotropium/olodaterol: addendum zum auftrag A15-31; auftrag A15-57. [Tiotropium/olodaterol - addendum to commission A15-31] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 358. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Benzoxazines; Bronchodilator Agents; Humans; Scopolamine

2016 Health Technology Assessment (HTA) Database.

13. Chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat)

Chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) Chronic obstructiv Chronic obstructive pulmonary disease: e pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) tiotropium/olodaterol (Spiolto Respimat) Evidence summary Published: 10 May 2016 nice.org.uk/guidance/esnm72 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in May 2016. See summaries of product characteristics (SPCs (...) ), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Summary Compared with its individual mono-components, a combination of tiotropium/olodaterol (Spiolto Respimat) has shown statistically significant improvements in lung function and health-related quality of life outcomes, although the clinical relevance of these improvements is unclear. There are no published studies which directly compare the efficacy and safety of tiotropium/olodaterol with other long-acting

2016 National Institute for Health and Clinical Excellence - Advice

14. Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial (Full text)

Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial Results from phase III clinical trials in adults and phase II clinical trials in children and adolescents demonstrate that tiotropium is an effective treatment when added to inhaled corticosteroid (ICS) maintenance therapy.We sought to assess the efficacy and safety of once-daily tiotropium Respimat added to ICSs with or without a leukotriene receptor antagonist in a phase III trial in adolescent (...) patients with moderate symptomatic asthma.In this 48-week, double-blind, placebo-controlled, parallel-group study, 398 patients aged 12 to 17 years were randomized to receive 5 μg (2 puffs of 2.5 μg) or 2.5 μg (2 puffs of 1.25 μg) of once-daily tiotropium or placebo (2 puffs) administered through the Respimat device every evening, each as add-on treatment to ICS background therapy, with or without a leukotriene receptor antagonist; long-acting β2-agonist therapy was not permitted during

2016 EvidenceUpdates PubMed

15. [Tiotropium/olodaterol: benefit assessment according to §35a Social Code Book V (dossier assessment)]

[Tiotropium/olodaterol: benefit assessment according to §35a Social Code Book V (dossier assessment)] Tiotropium/olodaterol – nutzenbewertung gemäß § 35a SGB V [Tiotropium/olodaterol: benefit assessment according to §35a Social Code Book V (dossier assessment)] Tiotropium/olodaterol – nutzenbewertung gemäß § 35a SGB V [Tiotropium/olodaterol: benefit assessment according to §35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Tiotropium/olodaterol – nutzenbewertung gemäß § 35a SGB V. [Tiotropium/olodaterol: benefit assessment according to §35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 337. 2015 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Benzoxazines

2016 Health Technology Assessment (HTA) Database.

16. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. (Full text)

Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Long-acting bronchodilators, comprising long-acting beta2-agonists (LABA) and long-acting anti-muscarinic agents (LAMA, principally tiotropium), are commonly used for managing persistent symptoms of chronic obstructive pulmonary disease (COPD). Combining these treatments, which have different mechanisms of action, may be more effective than (...) the individual components. However, the benefits and risks of combining tiotropium and LABAs for the treatment of COPD are unclear.To compare the relative effects on markers of quality of life, exacerbations, symptoms, lung function and serious adverse events in people with COPD randomised to LABA plus tiotropium versus tiotropium alone; or LABA plus tiotropium versus LABA alone.We searched the Cochrane Airways Group Specialised Register of trials and ClinicalTrials.gov up to July 2015.We included parallel

2015 Cochrane PubMed

17. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. (Full text)

Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Tiotropium and ipratropium bromide are both recognised treatments in the management of people with stable chronic obstructive pulmonary disease (COPD). There are new studies which have compared tiotropium with ipratropium bromide, making an update necessary.To compare the relative effects of tiotropium to ipratropium bromide on markers of quality of life, exacerbations, symptoms, lung function and serious adverse (...) events in patients with COPD using available randomised controlled trial (RCT) data.We identified RCTs from the Cochrane Airways Group Specialised Register of trials (CAGR) and ClinicalTrials.gov up to August 2015.We included parallel group RCTs of 12 weeks duration or longer comparing treatment with tiotropium with ipratropium bromide for patients with stable COPD.Two review authors independently assessed studies for inclusion and then extracted data on study quality and outcome results. We

2015 Cochrane PubMed

18. Tiotropium / olodaterol (Inspiolto Respimat)

Tiotropium / olodaterol (Inspiolto Respimat) Tiotropium / olodaterol | CADTH.ca Find the information you need Tiotropium / olodaterol Tiotropium / olodaterol Last Updated: October 9, 2018 Result type: Reports Project Number: SR0436-000 Product Line: Generic Name: Tiotropium / olodaterol Brand Name: Inspiolto Respimat Manufacturer: Boehringer Ingelheim (Canada) Ltd. Indications: Chronic Obstructive Pulmonary Disease (COPD) Submission Type: New Project Status: Complete Date Recommendation Issued

2015 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

19. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4) (Full text)

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4) Efficacy and safety of tiotropium+olodaterol fixed-dose combination (FDC) compared with the mono-components was evaluated in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in two replicate, randomised, double-blind, parallel-group, multicentre, phase III trials. Patients received tiotropium+olodaterol FDC 2.5/5 μg or 5/5 μg, tiotropium 2.5 μg or 5 μg, or olodaterol 5 μg (...) improvements in SGRQ total score versus the mono-components were only seen for tiotropium+olodaterol FDC 5/5 μg. Incidence of adverse events was comparable between the FDCs and the mono-components. These studies demonstrated significant improvements in lung function and health-related quality of life with once-daily tiotropium+olodaterol FDC versus mono-components over 1 year in patients with moderate to very severe COPD.Copyright ©ERS 2015.

2015 EvidenceUpdates PubMed

20. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study (Full text)

Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium for the treatment of COPD. The QUANTIFY study compared QVA149 with a free-dose (...) bronchodilator combination of tiotropium plus formoterol (TIO+FOR) in improving health-related quality of life (HRQoL) of patients with COPD.This multicentre, blinded, triple-dummy, parallel-group, non-inferiority study randomised patients aged ≥40 years with moderate-to-severe COPD (post-bronchodilator forced expiratory volume in 1 s (FEV1) ≥30% to <80% predicted) to QVA149 110/50 µg o.d. or TIO 18 µg o.d.+ FOR 12 µg twice daily (1:1) for 26 weeks. The primary endpoint was to demonstrate non-inferiority

2015 EvidenceUpdates PubMed